ST Hulubaby and its wholly-owned subsidiary Guangxi Weiwei have recently obtained drug registration certificates for cefditoren pivoxil granules, vonoprazan fumarate tablets, esomeprazole magnesium enteric-coated capsules, and sodium sulfate, magnesium sulfate, and potassium sulfate concentrated oral solution. Cumulative R&D investment for cefditoren pivoxil granules was 8.53 million yuan, for vonoprazan fumarate tablets was 9.63 million yuan, for esomeprazole magnesium enteric-coated capsules was 10.15 million yuan, and for the concentrated oral solution was 2.52 million yuan. In the first quarter of 2026, ST Hulubaby achieved revenue of 146 million yuan, with a net loss attributable to the parent company of 28.96 million yuan.
Hainan Huluwa Pharmaceutical Group Co LtdObtained registration certificates for four drugs, indicating product pipeline progress.
As subsidiary, obtained drug registration certificates, contributing to product portfolio.
